The open-label phase III IMpower 132 randomized nonsquamous NSCLC patients, without EGFR or ALK aberrations, to receive cisplatin/carboplatin plus pemetrexed and atezolizumab or chemotherapy alone. Here, ALK is linked to non-small cell lung carcinoma.